Time filter

Source Type

PubMed | Complutense University of Madrid, Camilo José Cela University, Institute of General Organic Chemistry CSIC Madrid and Hospital Universitario La Paz
Type: | Journal: Frontiers in aging neuroscience | Year: 2016

Stroke is a disease of aging affecting millions of people worldwide, and recombinant tissue-type plasminogen activator (r-tPA) is the only treatment approved. However, r-tPA has a low therapeutic window and secondary effects which limit its beneficial outcome, urging thus the search for new more efficient therapies. Among them, neuroprotection based on melatonin or nitrones, as free radical traps, have arisen as drug candidates due to their strong antioxidant power. In this

Loading Institute of General Organic Chemistry CSIC Madrid collaborators
Loading Institute of General Organic Chemistry CSIC Madrid collaborators